# Phase III Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-Angle Glaucoma or Ocular Hypertension Patients

> **NCT00288951** · PHASE3 · COMPLETED · sponsor: **Alcon Research** · enrollment: 690 (actual)

## Conditions studied

- Open-angle Glaucoma
- Ocular Hypertension

## Interventions

- **DRUG:** Travoprost 0.004% with and without BAK

## Key facts

- **NCT ID:** NCT00288951
- **Lead sponsor:** Alcon Research
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-10
- **Primary completion:** 2005-06
- **Final completion:** 2005-06
- **Target enrollment:** 690 (ACTUAL)
- **Last updated:** 2012-08-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00288951

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00288951, "Phase III Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-Angle Glaucoma or Ocular Hypertension Patients". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT00288951. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*